-
Is erenumab an efficient alternative for the prevention of episodic and chronic migraine in Spain? Results of a cost-effectiveness analysis J. Headache Pain (IF 7.4) Pub Date : 2024-03-15 Patricia Pozo-Rosich, José Luis Poveda, Carlos Crespo, María Martínez, José Manuel Rodríguez, Pablo Irimia
The reimbursement of erenumab in Spain and other European countries is currently restricted because of the cost of this novel therapy to patients with migraine who have experienced previous failures to traditional preventive treatments. However, this reimbursement policy should be preferably based on cost-effectiveness studies, among other criteria. This study performed a cost-effectiveness analysis
-
CGRP-monoclonal antibodies in Japan: insights from an online survey of physician members of the Japanese headache society J. Headache Pain (IF 7.4) Pub Date : 2024-03-15 Tsubasa Takizawa, Keiko Ihara, Narumi Watanabe, Ryo Takemura, Nobuyuki Takahashi, Naoki Miyazaki, Mamoru Shibata, Keisuke Suzuki, Noboru Imai, Norihiro Suzuki, Koichi Hirata, Takao Takeshima, Jin Nakahara
Anti-calcitonin gene-related peptide monoclonal antibodies (CGRPmAbs) have greatly changed migraine treatment options. In Japan, although CGRPmAb guidelines (≥ 4 monthly migraine days (MMDs) and ≥ 1 previous preventive failure) are well-acknowledged, the actual use of CGRPmAbs and the circumstances of the related headache care are unknown. We conducted an online survey of Japanese Headache Society
-
Societal and economic burden of migraine in Spain: results from the 2020 National Health and Wellness Survey J. Headache Pain (IF 7.4) Pub Date : 2024-03-15 David García-Azorín, Carlota Moya-Alarcón, Beatriz Armada, Margarita Sánchez del Río
The burden of migraine goes beyond the pain and associated symptoms. We aimed to describe the impact of migraine in healthcare resource utilization (HCRU), work productivity, and mood disorders, as well as its economic cost. Case–control study nested in a cross-sectional analysis of patient-reported data collected between 30/12/2019 and 20/04/2020 as part of the National Health and Wellness Survey
-
Specific cognitive and psychological alterations are more strongly linked to increased migraine disability than chronic migraine diagnosis J. Headache Pain (IF 7.4) Pub Date : 2024-03-15 Tatiana Castro Zamparella, Mariela Carpinella, Mario Peres, Florencia Patricia Cuello, Pilar Maza, Melanie Van Gansen, Marcelo Filipchuk, Verónica Balaszczuk, Carolina Maldonado, Pablo Scarnato, Diego Conci Magris, Marco Lisicki
The efficiency of The International Classification of Headache Disorders (ICHD-3) in reflecting patients’ disability has recently been questioned. This prompts consideration that clinical features beyond pain may more accurately indicate the extent of underlying brain impairment than the mere frequency of headache days. Important cognitive dysfunctions and psychological impairment have been reported
-
Calcitonin receptor, calcitonin gene-related peptide and amylin distribution in C1/2 dorsal root ganglia J. Headache Pain (IF 7.4) Pub Date : 2024-03-14 Tayla A. Rees, Zoe Tasma, Michael L. Garelja, Simon J. O’Carroll, Christopher S. Walker, Debbie L. Hay
The upper cervical dorsal root ganglia (DRG) are important for the transmission of sensory information associated with the back of the head and neck, contributing to head pain. Calcitonin receptor (CTR)-based receptors, such as the amylin 1 (AMY1) receptor, and ligands, calcitonin gene-related peptide (CGRP) and amylin, have been linked to migraine and pain. However, the contribution of this system
-
Safety and tolerability of atogepant for the preventive treatment of migraine: a post hoc analysis of pooled data from four clinical trials J. Headache Pain (IF 7.4) Pub Date : 2024-03-11 Paul Rizzoli, Michael J. Marmura, Jennifer Robblee, Jennifer McVige, Sara Sacco, Stephanie J. Nahas, Jessica Ailani, Rosa De Abreu Ferreira, Julia Ma, Jonathan H. Smith, Brett Dabruzzo, Messoud Ashina
Conventional, non-specific preventive migraine treatments often demonstrate low rates of treatment persistence due to poor efficacy or tolerability. Effective, well-tolerated preventive treatments are needed to reduce migraine symptoms, improve function, and enhance quality of life. Atogepant is a migraine-specific oral calcitonin gene–related peptide receptor antagonist that is indicated for the preventive
-
The glymphatic system in migraine and other headaches J. Headache Pain (IF 7.4) Pub Date : 2024-03-11 Maria Grazia Vittorini, Aysenur Sahin, Antonin Trojan, Sevil Yusifli, Tamta Alashvili, Gonçalo V. Bonifácio, Ketevan Paposhvili, Viktoria Tischler, Christian Lampl, Simona Sacco
Glymphatic system is an emerging pathway of removing metabolic waste products and toxic solutes from the brain tissue. It is made of a network of perivascular spaces, filled in cerebrospinal and interstitial fluid, encompassing penetrating and pial vessels and communicating with the subarachnoid space. It is separated from vessels by the blood brain barrier and from brain tissue by the endfeet of the
-
Decoding pain through facial expressions: a study of patients with migraine J. Headache Pain (IF 7.4) Pub Date : 2024-03-11 Wei-Ta Chen, Fu-Jung Hsiao, Gianluca Coppola, Shuu-Jiun Wang
The present study used the Facial Action Coding System (FACS) to analyse changes in facial activities in individuals with migraine during resting conditions to determine the potential of facial expressions to convey information about pain during headache episodes. Facial activity was recorded in calm and resting conditions by using a camera for both healthy controls (HC) and patients with episodic
-
AMPK activation attenuates central sensitization in a recurrent nitroglycerin-induced chronic migraine mouse model by promoting microglial M2-type polarization J. Headache Pain (IF 7.4) Pub Date : 2024-03-08 Guangshuang Lu, Shaobo Xiao, Fanchao Meng, Leyi Zhang, Yan Chang, Jinjing Zhao, Nan Gao, Wenjie Su, Xinghao Guo, Yingyuan Liu, Chenhao Li, Wenjing Tang, Liping Zou, Shengyuan Yu, Ruozhuo Liu
Energy metabolism disorders and neurogenic inflammation play important roles in the central sensitization to chronic migraine (CM). AMP-activated protein kinase (AMPK) is an intracellular energy sensor, and its activation regulates inflammation and reduces neuropathic pain. However, studies on the involvement of AMPK in the regulation of CM are currently lacking. Therefore, this study aimed to explore
-
Commentary on 2022 guidelines on clinical trial design in cluster headache and further suggestions J. Headache Pain (IF 7.4) Pub Date : 2024-03-07 Ioana Medrea, Stewart J. Tepper, Donliang Wang, Paul G. Mathew, Mark Burish
New guidelines for cluster headache clinical trials were recently published. We welcome these new guidelines and raise additional considerations in trial methodologies. We present non-inferiority trials to overcome ethical issues with placebo use, and additionally discuss issues with trial recruitment. We highlight some possible issues and solutions to be considered with the recently published cluster
-
One-year prevalence of cluster headache, hemicrania continua, paroxysmal hemicrania and SUNCT in Norway: a population-based nationwide registry study J. Headache Pain (IF 7.4) Pub Date : 2024-03-06 Knut Hagen
There is lack of population-based studies evaluating the prevalence of paroxysmal hemicrania, hemicrania continua and short-lasting unilateral neuralgiform headache attacks. The aim of this study was to investigate the gender-specific 1-year prevalence of cluster headache, paroxysmal hemicrania, hemicrania continua, and short-lasting unilateral neuralgiform headache attacks. A nationwide study was
-
The crucial role of locus coeruleus noradrenergic neurons in the interaction between acute sleep disturbance and headache J. Headache Pain (IF 7.4) Pub Date : 2024-03-05 Bozhi Li, Ya Cao, Huijuan Yuan, Zhe Yu, Shuai Miao, Chunxiao Yang, Zihua Gong, Wei Xie, Chenhao Li, Wenhao Bai, Wenjing Tang, Dengfa Zhao, Shengyuan Yu
Both epidemiological and clinical studies have indicated that headache and sleep disturbances share a complex relationship. Although headache and sleep share common neurophysiological and anatomical foundations, the mechanism underlying their interaction remains poorly understood. The structures of the diencephalon and brainstem, particularly the locus coeruleus (LC), are the primary sites where the
-
LncRNA Anxa10-203 enhances Mc1r mRNA stability to promote neuropathic pain by recruiting DHX30 in the trigeminal ganglion J. Headache Pain (IF 7.4) Pub Date : 2024-03-04 YaJing Liu, Fei Liu, YiKe Li, YueLing Li, YuHeng Feng, JiaShuo Zhao, Cheng Zhou, ChunJie Li, JieFei Shen, YanYan Zhang
Trigeminal nerve injury is one of the most serious complications in oral clinics, and the subsequent chronic orofacial pain is a consumptive disease. Increasing evidence demonstrates long non-coding RNAs (lncRNAs) play an important role in the pathological process of neuropathic pain. This study aims to explore the function and mechanism of LncRNA Anxa10-203 in the development of orofacial neuropathic
-
The impact of primary headaches on disability outcomes: a literature review and meta-analysis to inform future iterations of the Global Burden of Disease study J. Headache Pain (IF 7.4) Pub Date : 2024-03-04 Marta Waliszewska-Prosół, Danilo Antonio Montisano, Mariola Antolak, Federico Bighiani, Francescantonio Cammarota, Ilaria Cetta, Michele Corrado, Keiko Ihara, Regina Kartamysheva, Igor Petrušić, Maria Magdalena Pocora, Tsubasa Takizawa, Gloria Vaghi, Paolo Martelletti, Barbara Corso, Alberto Raggi
The burden and disability associated with headaches are conceptualized and measured differently at patients’ and populations’ levels. At the patients’ level, through patient-reported outcome measures (PROMs); at population level, through disability weights (DW) and years lived with a disability (YLDs) developed by the Global Burden of Disease Study (GBD). DW are 0–1 coefficients that address health
-
Harris Poll Migraine Report Card: population-based examination of high-frequency headache/migraine and acute medication overuse J. Headache Pain (IF 7.4) Pub Date : 2024-02-26 Amaal J. Starling, Roger Cady, Dawn C. Buse, Meghan Buzby, Charlie Spinale, Kathy Steinberg, Kevin Lenaburg, Steven Kymes
Migraine is a disabling neurologic disease that can fluctuate over time in severity, frequency, and acute medication use. Harris Poll Migraine Report Card was a US population-based survey to ascertain quantifiable distinctions amongst individuals with current versus previous high-frequency headache/migraine and acute medication overuse (HFM+AMO). The objective of this report is to compare self-reported
-
Postdromal symptoms in migraine: a REFORM study J. Headache Pain (IF 7.4) Pub Date : 2024-02-21 Janu Thuraiaiyah, Håkan Ashina, Rune Häckert Christensen, Haidar M. Al-Khazali, Messoud Ashina
Migraine is a multiphasic neurovascular disorder, where headache can be succeeded by postdromal symptoms. However, there are limited research on postdromal symptoms. This study aimed to investigate the proportion of individuals with migraine from a tertiary care unit reporting postdromal symptoms in adherence with the ICHD-3 definition. We also aimed to examine how the means of enquiry might influence
-
Associations of combined lifestyle index with migraine prevalence and headache frequency: a cross-sectional study from the MECH-HK study J. Headache Pain (IF 7.4) Pub Date : 2024-02-20 Yunyang Deng, Harry Haoxiang Wang, Fei Wan Ngai, Dexing Zhang, Jing Qin, Xiangyan Chen, Yao Jie Xie
Prior research has shown that individual lifestyles were associated with migraine. Yet, few studies focused on combined lifestyles, particularly in Chinese populations. This cross-sectional study aimed to investigate the relationships of a combined lifestyle index with migraine in Hong Kong Chinese women. Baseline data from a cohort study named Migraine Exposures and Cardiovascular Health in Hong Kong
-
Lipopolysaccharide, VE-cadherin, HMGB1, and HIF-1α levels are elevated in the systemic circulation in chronic migraine patients with medication overuse headache: evidence of leaky gut and inflammation J. Headache Pain (IF 7.4) Pub Date : 2024-02-19 Doga Vuralli, Merve Ceren Akgor, Hale Gok Dagidir, Ozlem Gulbahar, Meltem Yalinay, Hayrunnisa Bolay
Medication overuse headache (MOH) was recently shown to be associated with leaky gut in rodents. We aimed to investigate whether chronic migraine (CM) patients with MOH have elevated lipopolysaccharide levels and inflammatory molecules in blood circulation. The study included women participants (40 CM patients with NSAID overuse headache, 35 episodic migraine (EM) patients, and 20 healthy non-headache
-
Clinical features of migraine with aura: a REFORM study J. Headache Pain (IF 7.4) Pub Date : 2024-02-13 Andreas Vinther Thomsen, Håkan Ashina, Haidar M. Al-Khazali, Kathrine Rose, Rune Häckert Christensen, Faisal Mohammad Amin, Messoud Ashina
About one-third of persons with migraine experience transient neurologic symptoms, referred to as aura. Despite its widespread prevalence, comprehensive clinical descriptions of migraine with aura remain sparse. Therefore, we aimed to provide an in-depth phenotypic analysis of aura symptoms and characteristics in a cross-sectional study of a large sample of adults diagnosed with migraine with aura
-
Influence of metabolic state and body composition on the action of pharmacological treatment of migraine J. Headache Pain (IF 7.4) Pub Date : 2024-02-13 Noor Bruijn, Romy van Lohuizen, Malgorzata Boron, Mira Fitzek, Francesca Gabriele, Giada Giuliani, Laura Melgarejo, Pavel Řehulka, Gabriele Sebastianelli, Paul Triller, Simone Vigneri, Behiye Özcan, Antoinette Maassen van den Brink
Migraine is a disabling neurovascular disorder among people of all ages, with the highest prevalence in the fertile years, and in women. Migraine impacts the quality of life of affected individuals tremendously and, in addition, it is associated with highly prevalent metabolic diseases, such as obesity, diabetes mellitus and thyroid dysfunction. Also, the clinical response to drugs might be affected
-
Early and annual projected savings from anti-CGRP monoclonal antibodies in migraine prevention: a cost-benefit analysis in the working-age population J. Headache Pain (IF 7.4) Pub Date : 2024-02-12 Carlos Lazaro-Hernandez, Edoardo Caronna, Joana Rosell-Mirmi, Victor J Gallardo, Alicia Alpuente, Marta Torres-Ferrus, Patricia Pozo-Rosich
Migraine is one of the main causes of disability worldwide. Anti-CGRP monoclonal antibodies (MAbs) have proven to be safe and efficacious as preventive migraine treatments. However, their use is restricted in many countries due to their apparently high cost. Cost-benefit studies are needed. To study the cost-benefit of anti-CGRP MAbs in working-age patients with migraine. This is a prospective cohort
-
Treatment patterns and characteristics of patients with migraine: results from a retrospective database study in Japan J. Headache Pain (IF 7.4) Pub Date : 2024-02-08 Tsubasa Takizawa, Takahiro Kitano, Masahiro Iijima, Kanae Togo, Naohiro Yonemoto
Clinical characteristics and treatment practice of patients with migraine in Japan in real-world setting have not been fully investigated. We conducted a retrospective cohort study using claims database to understand the clinical practice of migraine in recent years and to characterize patients potentially not managed well by current treatment options. Our study used data from the large claims database
-
Factors associated to the presence of headache in patients with influenza infection and its consequences: a 2010–2020 surveillance-based study J. Headache Pain (IF 7.4) Pub Date : 2024-02-08 David García-Azorín, Laura Santana-López, José Eugenio Lozano-Alonso, Ana Ordax-Díez, Tomas Vega-Alonso, Diego Macias Saint-Gerons, Yésica González-Osorio, Silvia Rojo-Rello, José M. Eiros, Javier Sánchez-Martínez, Álvaro Sierra-Mencía, Andrea Recio-García, Alejandro Martín-Toribio, Ivan Sanz-Muñoz, Ángel Luis Guerrero-Peral
Headache is a common symptom of influenza infection; however, its causes and consequences remain uncertain. In this manuscript, we analyzed which demographic and clinical factors were associated with the presence of headache during the course of influenza infection and whether patients with headache had a different prognosis, evaluated by need of hospitalization, sick leave or school absenteeism. The
-
Dynamic changes in glymphatic function in reversible cerebral vasoconstriction syndrome J. Headache Pain (IF 7.4) Pub Date : 2024-02-05 Chia-Hung Wu, Yu Kuo, Yu-Hsiang Ling, Yen-Feng Wang, Jong-Ling Fuh, Jiing-Feng Lirng, Hsiu-Mei Wu, Shuu-Jiun Wang, Shih-Pin Chen
The pathophysiology of the reversible cerebral vasoconstriction syndrome (RCVS) remains enigmatic and the role of glymphatics in RCVS pathophysiology has not been evaluated. We aimed to investigate RCVS glymphatic dynamics and its clinical correlates. We prospectively evaluated the glymphatic function in RCVS patients, with RCVS subjects and healthy controls (HCs) recruited between August 2020 and
-
Comparison of effectiveness and safety of lasmiditan and CGRP-antagonists for the acute treatment of migraine in adults: systematic review and network meta-analysis of randomised trials J. Headache Pain (IF 7.4) Pub Date : 2024-02-05 Xinxin Deng, Liying Zhou, Cui Liang, Xue Shang, Xu Hui, Wendi Liu, Shanshan Liang, Yongsheng Wang, Meng Xu, Kangle Guo, Kehu Yang, Xiuxia Li
To compare the outcomes associated with the use of lasmiditan, rimegepant, ubrogepant, and zavegepant for the acute management of migraine headaches. We searched four electronic databases from database inception to August 31, 2023, to identify randomized controlled trials (RCTs) that report efficacy and safety for the acute treatment of migraine. The risk of bias in the included RCTs was evaluated
-
Validity and reliability of Arabic version of pediatric migraine disability assessment scale (Child Self-Report versus Parent Proxy-Report): a multi-center study J. Headache Pain (IF 7.4) Pub Date : 2024-02-05 Rehab Magdy, Amr Hassan, Zeinab Mohammed, Mohamed A. Abdeltwab, Nawal F. Abdel Ghaffar, Mona Hussein
Pediatric Migraine Disability Assessment (PedMIDAS) is one of the most frequently used questionnaires to assess disability from migraine in pediatric patients. This work aimed to evaluate the validity and test–retest reliability of the Arabic version of the child self-report versus the parent proxy report PedMIDAS. We also aimed to test the agreement between children's and parents' reports of the scale
-
Arterial hypertension in the chronic evolution of migraine: bystander or risk factor? An overview J. Headache Pain (IF 7.4) Pub Date : 2024-02-05 Federico Mazzacane, Gloria Vaghi, Matteo Cotta Ramusino, Giulia Perini, Alfredo Costa
Several risk factors are associated with the chronic evolution of migraine. Clinical and preclinical studies have provided data about the role of hypertension (HT) as one of the potential modifiable risk factors of chronic migraine (CM). This review is focused on the biological and clinical evidence supporting common mechanisms underlying HT and migraine and the potential role of HT in the transition
-
Real-world effectiveness of Anti-CGRP monoclonal antibodies compared to OnabotulinumtoxinA (RAMO) in chronic migraine: a retrospective, observational, multicenter, cohort study J. Headache Pain (IF 7.4) Pub Date : 2024-02-02 Licia Grazzi, Riccardo Giossi, Danilo Antonio Montisano, Mattia Canella, Marilena Marcosano, Claudia Altamura, Fabrizio Vernieri
Chronic migraine (CM) is a disabling condition with high prevalence in the general population. Until the recent approval of monoclonal antibodies targeting the calcitonin gene-related peptide (Anti-CGRP mAbs), OnabotulinumtoxinA (BoNT-A) was the only treatment specifically approved for CM prophylaxis. Direct comparisons between the two treatments are not available so far. We performed an observational
-
Health equity, care access and quality in headache – part 1 J. Headache Pain (IF 7.4) Pub Date : 2024-01-29 Claudio Tana, Bianca Raffaelli, Marcio Nattan Portes Souza, Elena Ruiz de la Torre, Daniel Gams Massi, Najib Kisani, David García-Azorín, Marta Waliszewska-Prosół
Current definitions of migraine that are based mainly on clinical characteristics do not account for other patient’s features such as those related to an impaired quality of life, due to loss of social life and productivity, and the differences related to the geographical distribution of the disease and cultural misconceptions which tend to underestimate migraine as a psychosocial rather than neurobiological
-
Migraine - a borderland disease to epilepsy: near it but not of it J. Headache Pain (IF 7.4) Pub Date : 2024-01-26 Jakob Paungarttner, Martina Quartana, Lucrezia Patti, Barbora Sklenárová, Fatemeh Farham, Inés Hernando Jiménez, M. Gokcen Soylu, Irina Maria Vlad, Semih Tasdelen, Teresa Mateu, Oreste Marsico, Federica Reina, Viktoria Tischler, Christian Lampl
Migraine and epilepsy are two paroxysmal chronic neurological disorders affecting a high number of individuals and being responsible for a high individual and socioeconomic burden. The link between these disorders has been of interest for decades and innovations concerning diagnosing and treatment enable new insights into their relationship. Although appearing to be distinct at first glance, both diseases
-
Calcitonin gene-related peptide antagonists in pregnancy: a disproportionality analysis in VigiBase® J. Headache Pain (IF 7.4) Pub Date : 2024-01-19 Roberta Noseda, Francesca Bedussi, Claudio Gobbi, Alessandro Ceschi, Chiara Zecca
Current evidence on the safety of calcitonin gene–related peptide antagonists (CGRP-A) in pregnancy for the treatment of both episodic and chronic migraine is scarce and does not yet provide definitive information. By querying VigiBase®, the World Health Organization global pharmacovigilance database, this study aimed to detect differences in the reporting frequency between CGRP-A and triptans in relation
-
Anti-CGRP antibody galcanezumab modifies the function of the trigeminovascular nocisensor complex in the rat J. Headache Pain (IF 7.4) Pub Date : 2024-01-19 Nadine Friedrich, Krisztina Németh, Martin Tanner, Judit Rosta, Ildikó Dobos, Orsolya Oszlács, Gábor Jancsó, Karl Messlinger, Mária Dux
Monoclonal antibodies directed against the neuropeptide calcitonin gene-related peptide (CGRP) are effective in the prevention of chronic and frequent episodic migraine. Since the antibodies do not cross the blood brain barrier, their antinociceptive effect is attributed to effects in meningeal tissues. We aimed to probe if such an antibody can be visualized within the dura mater and the trigeminal
-
Different vulnerability of fast and slow cortical oscillations to suppressive effect of spreading depolarization: state-dependent features potentially relevant to pathogenesis of migraine aura J. Headache Pain (IF 7.4) Pub Date : 2024-01-15 Tatiana M. Medvedeva, Maria P. Smirnova, Irina V. Pavlova, Lyudmila V. Vinogradova
Spreading depolarization (SD), underlying mechanism of migraine aura and potential activator of pain pathways, is known to elicit transient local silencing cortical activity. Sweeping across the cortex, the electrocorticographic depression is supposed to underlie spreading negative symptoms of migraine aura. Main information about the suppressive effect of SD on cortical oscillations was obtained in
-
Mechanosensitive receptors in migraine: a systematic review J. Headache Pain (IF 7.4) Pub Date : 2024-01-15 Adriana Della Pietra, Laura Gómez Dabó, Petr Mikulenka, Christian Espinoza-Vinces, Doga Vuralli, Isil Baytekin, Paolo Martelletti, Rashid Giniatullin
Migraine is a debilitating neurological disorder with pain profile, suggesting exaggerated mechanosensation. Mechanosensitive receptors of different families, which specifically respond to various mechanical stimuli, have gathered increasing attention due to their potential role in migraine related nociception. Understanding these mechanisms is of principal importance for improved therapeutic strategies
-
Involvement of the ipsilateral-to-the-pain anterior–superior hypothalamic subunit in chronic cluster headache J. Headache Pain (IF 7.4) Pub Date : 2024-01-11 Stefania Ferraro, Anna Nigri, Maria Grazia Bruzzone, Jean Paul Medina Carrion, Davide Fedeli, Greta Demichelis, Luisa Chiapparini, Giuseppe Ciullo, Ariosky Areces Gonzalez, Alberto Proietti Cecchini, Luca Giani, Benjamin Becker, Massimo Leone
Despite hypothalamus has long being considered to be involved in the pathophysiology of cluster headache, the inconsistencies of previous neuroimaging studies and a limited understanding of the hypothalamic areas involved, impede a comprehensive interpretation of its involvement in this condition. We used an automated algorithm to extract hypothalamic subunit volumes from 105 cluster headache patients
-
Double-blind, randomized, placebo-controlled study to evaluate erenumab-specific central effects: an fMRI study J. Headache Pain (IF 7.4) Pub Date : 2024-01-09 Hauke Basedau, Kuan-Po Peng, Marlene Schellong, Arne May
Given the findings of central effects of erenumab in the literature, we aimed to conduct a rigorous placebo-controlled, double-blind, randomized study to elucidate whether the observed changes are directly attributable to the drug. We recruited 44 patients with migraine, randomly assigning them to either the erenumab 70 mg or the placebo group. 40 patients underwent fMRI scanning using a trigeminal
-
Microglia TREM1-mediated neuroinflammation contributes to central sensitization via the NF-κB pathway in a chronic migraine model J. Headache Pain (IF 7.4) Pub Date : 2024-01-05 Songtang Sun, Zhenzhen Fan, Xuejiao Liu, Longde Wang, Zhaoming Ge
Neuroinflammation, mediated by the activation of microglia, contributes to central sensitization, which is associated with the development of chronic migraine (CM). TREM1 receptors amplify the inflammatory response. However, their relationship to CM is unclear. Thus, this study endeavoured to elucidate the exact role of TREM1 in CM. Nitroglycerin (NTG) was repeatedly administered intraperitoneally
-
Tryptophan metabolites and gut microbiota play an important role in pediatric migraine diagnosis J. Headache Pain (IF 7.4) Pub Date : 2024-01-05 Junhui Liu, Kaiyan Xi, Linlin Zhang, Mugu Han, Qingran Wang, Xinjie Liu
The pathogenesis of pediatric migraine remains unclear and presents challenges in diagnosis. Recently, growing evidence has indicated that the gut microbiota can exert modulatory functions at the gut-brain axis by directly or indirectly regulating tryptophan metabolism. Consequently, we aimed to elucidate the potential association among gut microbiota, tryptophan metabolism, and pediatric migraine
-
Dynamics and concordance alterations of regional brain function indices in vestibular migraine: a resting-state fMRI study J. Headache Pain (IF 7.4) Pub Date : 2024-01-05 Xing Xiong, Lingling Dai, Wen Chen, Jiajie Lu, Chunhong Hu, Hongru Zhao, Jun Ke
Prior MRI studies on vestibular migraine (VM) have revealed abnormalities in static regional intrinsic brain activity (iBA) and dynamic functional connectivity between brain regions or networks. However, the temporal variation and concordance of regional iBA measures remain to be explored. 57 VM patients during the interictal period were compared to 88 healthy controls (HC) in this resting-state functional
-
The World Health Organization Intersectoral Global Action Plan on Epilepsy and Other Neurological Disorders and the headache revolution: from headache burden to a global action plan for headache disorders J. Headache Pain (IF 7.4) Pub Date : 2024-01-04 Matilde Leonardi, Paolo Martelletti, Rami Burstein, Arianna Fornari, Licia Grazzi, Alla Guekht, Richard B. Lipton, Dimos Dimitrios Mitsikostas, Jes Olesen, Mayowa Ojo Owolabi, Elena Ruiz De la Torre, Simona Sacco, Timothy J. Steiner, Nirmal Surya, Takao Takeshima, Cristina Tassorelli, Shuu-Jiun Wang, Tissa Wijeratne, Shengyuan Yu, Alberto Raggi
The World Health Organization (WHO) Intersectoral Global Action Plan on Epilepsy and Other Neurological Disorders was developed by WHO to address the worldwide challenges and gaps in provision of care and services for people with epilepsy and other neurological disorders and to ensure a comprehensive, coordinated response across sectors to the burden of neurologic diseases and to promote brain health
-
Correction: Mechanisms of initiation of cortical spreading depression J. Headache Pain (IF 7.4) Pub Date : 2023-12-20 Marina Vitale, Angelita Tottene, Maral Zarin Zadeh, K. C. Brennan, Daniela Pietrobon
Correction: J Headache Pain 24, 105 (2023) https://doi.org/10.1186/s10194-023-01643-9 In the original version of this article [1], on page 2, in the second paragraph of the right-hand column, the text reads: “ On the other hand, mutant mice carrying mutations, which cause partial loss-of-function of CaV2.1 channels and reduced K+-evoked glutamate rise, showed a lower CSD stimulation threshold” but
-
Association between impaired dynamic cerebral autoregulation and BBB disruption in reversible cerebral vasoconstriction syndrome J. Headache Pain (IF 7.4) Pub Date : 2023-12-19 Yu-Hsiang Ling, Nai-Fang Chi, Li-Ling Hope Pan, Yen-Feng Wang, Chia-Hung Wu, Jiing-Feng Lirng, Jong-Ling Fuh, Shuu-Jiun Wang, Shih-Pin Chen
Half of the sufferers of reversible cerebral vasoconstriction syndrome (RCVS) exhibit imaging-proven blood-brain barrier disruption. The pathogenesis of blood-brain barrier disruption in RCVS remains unclear and mechanism-specific intervention is lacking. We speculated that cerebrovascular dysregulation might be associated with blood-brain barrier disruption in RCVS. Hence, we aimed to evaluate whether
-
Machine learning approach for Migraine Aura Complexity Score prediction based on magnetic resonance imaging data J. Headache Pain (IF 7.4) Pub Date : 2023-12-18 Katarina Mitrović, Andrej M. Savić, Aleksandra Radojičić, Marko Daković, Igor Petrušić
Previous studies have developed the Migraine Aura Complexity Score (MACS) system. MACS shows great potential in studying the complexity of migraine with aura (MwA) pathophysiology especially when implemented in neuroimaging studies. The use of sophisticated machine learning (ML) algorithms, together with deep profiling of MwA, could bring new knowledge in this field. We aimed to test several ML algorithms
-
The burden and trends of headache disorders among the population aged 15–39: a study from 1990 to 2019 J. Headache Pain (IF 7.4) Pub Date : 2023-12-13 Ruixia Yuan, Zhuang Tong, Guoliang Xiang, Yingying Xie, Kaixiang Li, Liang Zhang, Xueqing Wang
To analyze the global burden of headache disorders in adolescents and young adults (AYAs). Data of headache disorders in the 15–39 age groups were extracted from GBD 2019. The age-standardized rates (ASRs) of incidence, prevalence, and years lived with disability (YLDs) rate were used to describe the burden. Estimated Annual Percentage Changes (EAPCs) were used to describe the trend from 1990 to 2019
-
Health equity, care access and quality in headache – part 2 J. Headache Pain (IF 7.4) Pub Date : 2023-12-13 Bianca Raffaelli, Eloísa Rubio-Beltrán, Soo-Jin Cho, Roberto De Icco, Alejandro Labastida-Ramirez, Dilara Onan, Raffaele Ornello, Ruth Ruscheweyh, Marta Waliszewska-Prosół, Roberta Messina, Francesca Puledda
Headache disorders are a global public health concern affecting diverse populations. This review examines headache service organizations in low-, middle-, and high-income countries. It addresses global challenges in pharmacological headache treatment, with a focus on safety, tolerability, reproductive and child health, and outlines disparities in accessing innovative treatments worldwide. Organized
-
Association of intradialysis blood sodium level, blood pressure variability, and hydration status with hemodialysis-related headache: a prospective cohort study J. Headache Pain (IF 7.4) Pub Date : 2023-12-11 Yuqin Xiong, Nujia You, Ruoxi Liao, Ling Wu, Yao Liu, Ziying Ling, Yang Yu
To identify primary factors contributing to hemodialysis-related headache (HRH) in maintenance hemodialysis (MHD) patients. Adult outpatients receiving MHD were prospectively enrolled from a hemodialysis (HD) center of a tertiary hospital in China. Twelve dialysis sessions were successively monitored for each patient. HRH is defined as having at least three headache episodes that begin during HD and
-
Compromised trigemino-coerulean coupling in migraine sensitization can be prevented by blocking beta-receptors in the locus coeruleus J. Headache Pain (IF 7.4) Pub Date : 2023-12-08 Jérémy Signoret-Genest, Maxime Barnet, François Gabrielli, Youssef Aissouni, Alain Artola, Radhouane Dallel, Myriam Antri, Philip Tovote, Lénaïc Monconduit
Migraine is a disabling neurological disorder, characterized by recurrent headaches. During migraine attacks, individuals often experience sensory symptoms such as cutaneous allodynia which indicates the presence of central sensitization. This sensitization is prevented by oral administration of propranolol, a common first-line medication for migraine prophylaxis, that also normalized the activation
-
Clinical effectiveness of pharmacological interventions for managing chronic migraine in adults: a systematic review and network meta-analysis J. Headache Pain (IF 7.4) Pub Date : 2023-12-06 Seyran Naghdi, Martin Underwood, Jason Madan, Anna Brown, Callum Duncan, Manjit Matharu, Aiva Aksentyte, Natasha Davies, Sophie Rees, Andrew Cooklin, Amy Grove, Hema Mistry
Chronic migraine can be a profoundly disabling disorder that may be treated with preventive medications. However, uncertainty remains as to which preventive medication is the most effective. We present a network meta-analysis to determine the effectiveness and rank of preventive drugs for chronic migraine in adults. We identified, reviewed, and extracted data from randomised controlled trials (RCTs)
-
Mapping brain functional networks topological characteristics in new daily persistent headache: a magnetoencephalography study J. Headache Pain (IF 7.4) Pub Date : 2023-12-06 Dong Qiu, Zhaoli Ge, Yanliang Mei, Wei Wang, Zhonghua Xiong, Xiaoshuang Li, Ziyu Yuan, Peng Zhang, Mantian Zhang, Xin Liu, Yaqing Zhang, Xueying Yu, Hefei Tang, Yonggang Wang
The brain functional network topology in new daily persistent headache (NDPH) is not well understood. In this study, we aim to assess the cortical functional network topological characteristics of NDPH using non-invasive neural signal recordings. Resting-state magnetoencephalography (MEG) was used to measure power fluctuations in neuronal oscillations from distributed cortical parcels in 35 patients
-
What to do with non-responders to CGRP(r) monoclonal antibodies: switch to another or move to gepants? J. Headache Pain (IF 7.4) Pub Date : 2023-12-05 Marta Waliszewska-Prosół, Doga Vuralli, Paolo Martelletti
In this editorial we aim to provide potential therapeutic options in patients who do not benefit from treatment with CGRP(r) monoclonal antibodies. Based on current real-life studies and analysis of practical and economic aspects, we will analyze the potential benefits of changing CGRP-targeted treatment.
-
Competing treatments for migraine: a headache for decision-makers J. Headache Pain (IF 7.4) Pub Date : 2023-12-05 Hema Mistry, Seyran Naghdi, Martin Underwood, Callum Duncan, Jason Madan, Manjit Matharu
Migraine is the world’s second most common disabling disorder, affecting 15% of UK adults and costing the UK over £1.5 billion per year. Several costly new drugs have been approved by National Institute for Health and Care Excellence. To assess the cost-effectiveness of drugs used to treat adults with chronic migraine. We did a systematic review of placebo-controlled trials of preventive drugs for
-
Translation, cross-cultural adaptation and measurement proprieties of the German version of the Allodynia Symptom Checklist (ASC-12) J. Headache Pain (IF 7.4) Pub Date : 2023-12-01 Tetiana Marusich, Tibor M Szikszay, Anne Sennholz, Kerstin Luedtke, Gabriela F. Carvalho
Cutaneous allodynia is highly prevalent among migraineurs and is associated with a poor prognosis. The Allodynia Symptom Checklist (ASC-12) is a comprehensive questionnaire to identify the presence and severity of allodynia. Our aim was to translate and adapt the ASC-12 to German and evaluate its measurement properties. Following the COSMIN guidelines, 80 migraine patients were enrolled in the study
-
Headaches during pregnancy and the risk of subsequent stroke J. Headache Pain (IF 7.4) Pub Date : 2023-12-01 Ki-Woong Nam, Sungyeon Ha, Min-Jeong Oh, Kyungmi Oh, Chi Kyung Kim, Geum Joon Cho, Young Seo Kim, Cheryl D. Bushnell
Primary headache disorder is a known risk factor for stroke in women and usually improves during the first trimester of pregnancy. However, despite this, some women develop headaches during pregnancy (G-HA), and the effect of this headache on subsequent stroke is unknown. In this study, we evaluated the association between G-HA and stroke after delivery in women. Based on the Korean National Health
-
Trends in migraine incidence among women of childbearing age from 1990 to 2019 and the prediction for 2030: an analysis of national data in China J. Headache Pain (IF 7.4) Pub Date : 2023-11-27 Zhuanzhuan Fan, Jian Kang, Wenting Li, Zhiyong Wang, Huifen Qiao, Fei Xu
Migraine is a primary headache, which has been producing heavy disease burden globally. There is no data on the incidence of migraine among women of childbearing age worldwide, including China. This study aimed to investigate the time trend in incidence rate of migraine among women of childbearing age in China from 1999 to 2019, and to make a prediction for 2030. Data on migraine incidence and population
-
Long-term effectiveness and tolerability of galcanezumab in patients with migraine excluded from clinical trials: real world evidence of 1055 patients with 1 year follow-up from the Galca-Only registry J. Headache Pain (IF 7.4) Pub Date : 2023-11-22 Victor Obach, Fernando Velasco, Rocio Alvarez Escudero, María Martín Bujanda, Sonsoles Aranceta, Neus Fabregat, Teresa Marco, Aintzine Ruisanchez, Natalia Roncero, Ane Mínguez-Olaondo, Marta Ruibal, Daniel Guisado-Alonso, Antia Moreira, Elisa Cuadrado-Godia, Amaya Echeverria, Izaro Kortazar Zubizarreta, Alba López-Bravo, Nuria Riesco, Lucia González-Fernández, Nuria Pola, Paula Manera, Ángel Luis Guerrero-Peral
Galcanezumab has shown efficacy and effectiveness in the treatment of episodic and chronic migraine (CM), however, the population represented in randomized clinical trials (RCTs) differs from the population observed in real-world setting. To describe the long-term effectiveness and tolerability of galcanezumab in clinical practice in patients excluded from RCTs. Multicenter prospective cohort study
-
Correction: Global, regional, and national epidemiology of migraine and tension-type headache in youths and young adults aged 15–39 years from 1990 to 2019: findings from the global burden of disease study 2019 J. Headache Pain (IF 7.4) Pub Date : 2023-11-22 Xin-yu Li, Cheng-hao Yang, Jia-jie Lv, Hui Liu, Lu-yu Zhang, Min-yi Yin, Zhi-lin Guo, Ru-hong Zhang
Correction: J Headache Pain 24, 126 (2023) https://doi.org/10.1186/s10194-023-01659-1 All data in this article [1] has been sourced from the Global Burden of Disease (GBD) database. While the authors adhered to IHME's terms of use and guidelines (https://www.healthdata.org/Data-tools-practices/data-practices/ihme-free-charge-non-commercial-user-agreement), the source identifier required by the agreement
-
Long-term effectiveness of eptinezumab in patients with migraine and prior preventive treatment failures: extension of a randomized controlled trial J. Headache Pain (IF 7.4) Pub Date : 2023-11-20 Messoud Ashina, Stewart J. Tepper, Astrid Gendolla, Bjørn Sperling, Anders Ettrup, Mette Krog Josiassen, Amaal J. Starling
Eptinezumab demonstrated efficacy in adults with migraine and prior preventive treatment failures in the placebo-controlled phase of the DELIVER clinical trial; its long-term effectiveness in this population has not yet been reported. The objective of this study was to evaluate the long-term effectiveness of eptinezumab in a migraine patient population during the 48-week extension phase of DELIVER
-
Progesterone distribution in the trigeminal system and its role to modulate sensory neurotransmission: influence of sex J. Headache Pain (IF 7.4) Pub Date : 2023-11-14 Aida Maddahi, Karin Warfvinge, Anja Holm, Jacob C. A. Edvinsson, Philip Victor Reducha, Spyridoula Kazantzi, Kristian A. Haanes, Lars Edvinsson
Women are disproportionately affected by migraine, representing up to 75% of all migraine cases. This discrepancy has been proposed to be influenced by differences in hormone levels between the sexes. One such hormone is progesterone. Calcitonin gene-related peptide (CGRP) system is an important factor in migraine pathophysiology and could be influenced by circulating hormones. The purpose of this
-
Treatment patterns for patients initiating novel acute migraine specific medications (nAMSMs) in the context of monoclonal antibodies (mAbs) targeting the calcitonin gene-related peptide (CGRP) pathway J. Headache Pain (IF 7.4) Pub Date : 2023-11-09 Zifan Zhou, Robert Urman, Karminder Gill, Andrew S. Park, Fiston Vuvu, Leah B. Patel, Jingsong Lu, Rolin L. Wade, Lindsay Frerichs, Mark E. Bensink
New acute and preventive migraine medications are available, but data on current treatment patterns are limited. This study describes migraine treatment patterns among patients initiating novel acute migraine specific medications (nAMSMs), overall and by prior use of anti-calcitonin gene-related peptide (CGRP) pathway monoclonal antibodies (mAbs). In this retrospective cohort study using IQVIA open-source
-
One-year prospective real-world assessment of effectiveness and safety of erenumab in migraine prevention: results of the French FHU INOVPAIN registry study J. Headache Pain (IF 7.4) Pub Date : 2023-11-08 M. Lanteri-Minet, R. Fabre, C. Martin, K. Pradat, A. Alchaar, E. Bozzolo, M. L. Duchene, E. K. Van Obberghen, A. Donnet, D. Fontaine
Randomized clinical trials have demonstrated efficacy and safety of erenumab. The aim of this study is to evaluate the effectiveness and safety of erenumab in a real-world setting in French patients with migraine associated with extreme unmet needs. This is a one year-prospective real-word study with enrolment of all consecutive adult patients included in the FHU InovPain registry who participated